CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief Executive Officer, Brad Hauser. As part of the segment, Mr. Hauser discusses Autonomix’s publication ...

Performance in 2025 was characterized by resilience in softer markets, with a strong fourth-quarter exit driven by a productive launch cycle across Surgical and Vision Care. The Unity platform represents the largest upgrade opportunity in the surgical portfolio in over a decade, designed to increase throughput and case efficiency for surgeons. PanOptix Pro has successfully stabilized trifocal share in the U.S. by addressing surgeon concerns regarding light scatter and visual disturbance profiles. St ...

Inogen, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Transformation and Performance Drivers Achieved a strategic pivot from a single-product oxygen company to a diversified respiratory platform spanning oxygen, sleep therapy, airway clearance, and digital health. Delivered first full year of positive adjusted EBITDA since 2021, driven by disciplined cost management and operational leverage from a 4% revenue increase. Attributed 20% unit volume growth to the ongoing market conversion from trad ...

Revenue nearly tripled since 2021, driven by aggressive expansion in medical submarkets including robotic surgery and safe patient handling. Performance in 2025 was impacted by $6.3 million in labor inefficiencies at the Illinois AJR facility following E-Verify attrition issues, though Q4 saw these costs more than halve compared to Q3. Strategic shift of production to the Dominican Republic continues to drive profitability, benefiting from a zero-percent effective income tax rate in that jurisdiction. ...

The London Company, an investment management company, released its fourth-quarter 2025 investor letter for its “The London Company Mid Cap Strategy”. A copy of the letter can be downloaded here. In Q4 2025, US equities posted the third consecutive quarter of higher returns, with the Russell 3000 Index rising 2.4%. The market highlighted how investors balanced the optimism on earnings growth and concerns regarding AI returns and cooling macroeconomic factors. In the quarter, the portfolio returned 3.2% (3.0% ...

Core Insights - Cochlear North America celebrates International Cochlear Implant Day by announcing the 2026 Cochlear Academic Scholarship recipients, highlighting the achievements of students who are also users of Cochlear's hearing systems [1] Scholarship Recipients - Eight students were awarded scholarships for their academic excellence and community impact, showcasing the potential of cochlear implant users [1] - The Graeme Clark Scholarship recognizes outstanding Cochlear Nucleus Implant recipients, with winners including: - Viktor D. from Cornell University, aiming to study Materials Science or Biomedical Engineering [1] - Sofia O. from Dalhousie University, pursuing an MSc in Audiology and focusing on hearing-fatigue research [1] - Sadie P. from Oklahoma State University, planning to study Biochemistry/Molecular Biology [1] - Marley V.P. from Yale University, studying Finance and Global Affairs with a focus on disability inclusion [1] - Fateha C. from the University of Houston, pursuing Computer Information Systems [1] - The Anders Tjellström Scholarship honors Baha and Osia System recipients, with winners including: - Peyton S. from Utah State University, aspiring to be an interior designer [1] - Kaitlin B. from the University of California Irvine, pursuing Biomedical Engineering and premedical studies [1] - The Cochlear Americas Vocational Scholarship supports students in technical or vocational schools, with Lailoni C. from Franklin Hair Academy aiming to become an inclusive cosmetologist [1] Scholarship Details - Each scholarship recipient will receive $2,000 per year for up to four years, reflecting Cochlear's commitment to education and innovation [1] Company Overview - Cochlear Limited has helped over 750,000 people in more than 180 countries since 1981, establishing itself as a global leader in implantable hearing solutions [1] - The company has invested over AUD$3 billion in research and development to advance hearing technology [1]

IP and technology acquisition is expected to be highly accretive and to advance Lifeward’s position as a diversified biomedical innovation companyWill Expand Lifeward’s portfolio beyond lower-limb solutions, creating a differentiated, whole-body neuro-rehabilitation portfolio Will Strengthen long-term strategic networks with neuro-rehabilitation prescribers, rehabilitation networks, and payers HUDSON, Mass. and YOKNEAM ILLIT, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” ...

Core Viewpoint - MiniMed has launched an initial public offering (IPO) to strengthen its capital reserves as it separates from parent company Medtronic, with shares expected to be priced between $25 and $28 [1]. Group 1: IPO Details - MiniMed will offer 28 million shares of common stock on the Nasdaq Global Select Market under the ticker "MMED" [1]. - Underwriters will have a 30-day option to purchase up to 4.2 million additional shares at the IPO price minus underwriting discounts and commissions [2]. - Post-IPO, Medtronic will retain ownership of 88.70% to 90.03% of MiniMed's shares, depending on underwriter purchases [2]. Group 2: Financial Use of Proceeds - Medtronic plans to allocate approximately $350 million of the net proceeds from the IPO for general corporate purposes, with the remainder directed towards repaying MiniMed's intercompany debt [3]. - The intercompany debt was incurred after Medtronic transferred assets to MiniMed following their strategic split in May 2025 [3][4]. Group 3: Company Performance - MiniMed reported $2.7 billion in annual revenue for fiscal year 2025, alongside a net loss of $198 million [4]. Group 4: Competitive Positioning - As MiniMed aims to establish itself as a leading diabetes device provider, it faces competition from Abbott Laboratories and Dexcom but may benefit from its comprehensive insulin management ecosystem [5]. - The company has made advancements in its insulin delivery system, MiniMed 780G, which received FDA clearance and Medicare access in February 2026 [6]. Group 5: Future Developments - MiniMed is developing third-generation automated insulin delivery systems, including the MiniMed Flex insulin pump, which has been submitted for FDA approval [7]. - The company anticipates filing for CE mark approval for the insulin pump in Q1 2026 and plans to seek FDA approval for its Fit patch pump in the fall of 2026 [7].

This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter. ARLINGTON, Texas — Though the jury is still out on the long-term implications of the latest artificial intelligence tools, it’s hard not to see some parallels to the Theranos scandal. The medical device company run by convicted fraudster Elizabeth Holmes was full of promise, claiming to have developed a finger-prick blood test that could screen for a range of diseases and d ...

/PRNewswire/ -- Polaroid Therapeutics (PTx) annonce aujourd'hui que POLTX_Fiber a reçu le marquage CE en tant que dispositif médical de classe IIb avec APT ...